Laboratorios Richmond S.A.C.I.F. Overview
Laboratorios Richmond is a mid-sized, founder-controlled Argentine pharmaceutical group. Market commentary describes it as the only Argentine-owned laboratory listed on the Buenos Aires exchange. Its core franchise is high-cost specialty generics: it leads the Argentine HIV/infectious-disease market with a 56.9% share (company data via FIX SCR, December 2025). Its strategy centres on being first to launch generics, fixed-dose combinations and biosimilars, alongside oncology, central nervous system and cardiometabolic portfolios. Since 2021 Richmond has been transforming itself into a biotechnology and vaccine manufacturer. It produced Sputnik V locally during the pandemic and then built the roughly USD 85 million, trust-financed "VIDA" vaccine plant in Pilar. VIDA was licensed by ANMAT in May 2025 and made its first commercial sales in March 2026. The investment thesis is a trade-off: the core business is high-margin (company-adjusted EBITDA of 34% in FY2025), but the balance sheet is leveraged, USD-exposed and liquidity-constrained. Equity value now depends heavily on VIDA's commercial ramp-up.
Company's own description (paraphrased from the FY2025 results report and rating-agency business profile). Richmond describes itself as an Argentine-owned pharmaceutical company with regional reach and roughly nine decades of history. It develops, manufactures and markets complex medicines for HIV and infectious diseases (including hepatitis C), oncology and onco-hematology, central nervous system disorders, cardiometabolic disease, ophthalmology and other specialty areas (multiple sclerosis, rheumatoid arthritis, hospital products). It has recently added vaccines and biotechnology products through the VIDA plant.
The company reports that about 95% of its products are developed in-house by its R&D department. Its high-cost lines focus on launching the first generic in Argentina, on biosimilars, and on innovative combinations that improve patient adherence, such as single-tablet fixed-dose combinations (FIX SCR, 22-Jul-2026).
Portfolio scale.
-
86 products (in various strengths and presentations) in Argentina across six business lines (FIX SCR).
-
87 medicinal articles in 2025, down from 90 in 2024 (FIX SCR).
-
373 marketing authorisations across markets (FIX SCR, 2026), up from 366 (company institutional presentation, ON Serie VI, 2024).
-
Products sold in 26 countries per the 2024 presentation.
Business model and revenue model. Richmond is essentially a product company. Revenue comes overwhelmingly from manufacturing and selling branded generics and specialty medicines. Three secondary streams exist or are emerging:
In-licensed products: Three innovative products are licensed from Ever Pharma (Austria) and Pharmacosmos (Denmark), and seven vaccine technologies from CanSino Biologics (2), Sinovac (2), BioNet (1) and Biological E (1) (FIX SCR).
Contract manufacturing ("maquila"): FIX SCR's 2024 report noted that the VIDA plant is designed to provide productive services to other pharmaceutical laboratories.
Distribution of third-party medical devices: Since July 2026 Richmond is exclusive Argentine distributor of the OraSure OraQuick HIV self-test (hecho relevante, 13-Jul-2026).
There is no subscription revenue. Licensing income from out-licensing is not publicly disclosed.
Value-chain position. Richmond is vertically integrated from formulation R&D through manufacturing (oral solids, high-potency oral solids, lyophilised injectables, and now biologics/vaccines at VIDA) to marketing and distribution. It is not an active pharmaceutical ingredient (API) producer at scale. About 60% of production costs and 83% of trade payables are in foreign currency, reflecting dependence on imported inputs (FIX SCR, 2026). Hetero Labs (India), an alliance partner for more than 25 years per 2021 press, is a historical supply and technology partner.
End-markets. Argentina's prescription pharmaceutical market (with a dominant position in HIV antiretrovirals), Argentine public health procurement, and Latin American markets through subsidiaries in Colombia, Chile, Paraguay, Mexico and Peru, a holding company in Uruguay, an Italian entity (details not disclosed), and 28 strategic distribution partners (FIX SCR, 2026).
Independent characterisation. Richmond has three distinct business layers:
- A highly profitable, niche, high-cost specialty-generic business. Its HIV dominance and first-generic strategy give it pricing power in a market where reimbursers pay for expensive therapies.
A sub-scale regional platform: Exports remain about 5% of sales. The 2025 exit from Colombian manufacturing shows retrenchment rather than expansion.
A large, capital-intensive biotech/vaccine bet (VIDA): It is financed off the core balance sheet through a trust but is economically consolidated. It dominates the risk profile: VIDA-related trust debt of about USD 106 million is 68% of group debt (FIX SCR).
The core business's EBITDA margin expanded to 31.8% in 2025 (FIX basis). Group net income, however, is driven by financial results tied to the peso/dollar/inflation mix, because 82–83% of financial liabilities are USD-denominated or USD-linked.
Strategy
Stated strategic themes (paraphrased from the FY2025 results report, H1-2026 results and FIX SCR's business profile):
-
Grow market share in high-cost specialty therapies through first-to-market generics, fixed-dose combinations that improve adherence, and biosimilars. Management credits this focus and the capture of new market opportunities for the FY2025 margin expansion.
-
Operational efficiency. Productivity and cost programmes cut real COGS by 11.7% in FY2025, and administrative expenses fell in real terms in 2025 (-3.7%) and H1-2026 (-14.5%) after reorganisation work was completed.
-
Transformation into a biotech and vaccine company through VIDA. The company wants to move beyond traditional drugs into vaccines, biosimilars and biologics for the local market and for export. Management expects vaccines to reach up to 35% of revenues in coming years (per FIX SCR, citing company expectations).
-
Regional and export expansion as a natural USD hedge. Exports and foreign-subsidiary sales are described as the main growth focus. The model is shifting from local manufacturing abroad (Colombia exit) to exporting Argentine-made products through commercial subsidiaries.
-
Portfolio adjacency. The company is entering medical devices and diagnostics, starting with exclusive distribution of OraQuick, to leverage its HIV franchise and become a regional distribution partner.
-
Sustainability alignment. Management frames its development compass around the UN/WHO Sustainable Development Goals. VIDA is financed partly through a sustainable bond and targets LEED Gold.
Medium-term financial targets and guidance. Richmond does not publish formal numerical guidance. Implied targets and external expectations:
-
Management expects ratios (net debt/EBITDA, profitability) to normalise as VIDA sales materialise and as inflation and the exchange rate converge (FY2025 and H1-2026 reports).
-
FIX SCR base case (not company guidance):
-
2026 EBITDA margin slightly below 20%, recovering to about 25% thereafter.
-
Debt/EBITDA about 8x in 2026 (about 2x ex-VIDA trust), deleveraging afterwards.
-
VIDA gaining traction gradually in 2026 and reaching profitability in 2027.
-
FCF trending towards neutral or positive as capex falls.
-
Products & Services
Disclosure note. Richmond does not publish product-level revenue, pricing or launch-year data in the sources reviewed. Brand names below come from S&P Capital IQ's business description (via MarketScreener) and company presentations. Pricing for all products is regulated or negotiated with payers and is not publicly disclosed.
HIV and Infectology (20 products; market leader with 56.9% share)
| Brand | Description / disclosed facts | Launch / version year |
|---|---|---|
| Tri-Zevuvir® | Dolutegravir + emtricitabine + tenofovir alafenamide (TAF) fixed-dose combination; presented by the company as a leading high-cost case. Press reports an Argentine single-daily-tablet HIV treatment approved by ANMAT | 2022 (company presentation) |
| Mivuten | Antiretroviral; historic public-sector supply contract for 900,000 units worth ARS 28.8 million (c. 2017) | — |
| Ciganclor | Antiviral | — |
| Lazinevir | Antiviral | — |
| Leuzan | Antiviral | — |
| Probirase | Antiviral | — |
| Protease | Antiviral | — |
| Selmivir | Antiviral | — |
| Trivenz | Antiviral | — |
| Virontar / Virontar N / Virontar 600 | Antiviral family, several strengths | — |
| Vuclodir | Antiviral | — |
| Zepril | Antiviral | — |
| Zetavudin | Antiviral | — |
| Zetrotax | Antiviral | — |
| Hepatitis C (HCV) antivirals | Sold mainly through public tenders together with HIV (FIX SCR); brands not disclosed | — |
| OraQuick® HIV Self-Test (distributed) | In-vitro oral-fluid self-test for HIV-1/HIV-2 antibodies by OraSure Technologies (US). FDA-approved over the counter and WHO-prequalified. Richmond is exclusive Argentine distributor; this is Richmond's first medical-device line | ANMAT clearance 13-Jul-2026 |
Target customers: obras sociales, prepagas, the national HIV programme (public tenders), and export markets.
Oncology and Onco-hematology (24 products)
| Brand | Description / disclosed facts | Year |
|---|---|---|
| Bemux | Oncology | — |
| Capecit | Oncology | — |
| Doxetal | Oncology | — |
| Drifen | Oncology | — |
| Espasevit | Oncology | — |
| Fontrax | Oncology | — |
| Gezt | Oncology | — |
| Monofer | Listed by S&P Capital IQ within oncology/onco-hematology. Monofer is a Pharmacosmos (Denmark) brand, consistent with FIX's mention of a Pharmacosmos licence | — |
| High-potency oral solids range | Produced at the dedicated high-potency plant in Pilar, partly financed by ON Serie III (2020) | Plant completion date not disclosed |
| Lyophilised injectables | Produced at the lyophilisation plant (Laboratorios Richmond División Liofilizados) | — |
Target customers: private and institutional high-cost payers, and hospitals. Market share was 1.1% (rank 19 of 59 laboratories) per 2022 data; the company expected to improve this via its high-potency plant.
Central Nervous System / Neuropsychiatry (15 products)
| Brand | Description | Year |
|---|---|---|
| Dalam 15 | Neuropsychiatric; "Dalam" is also listed under hospital products | — |
| Dolofrix 10 | Analgesic / neuro | — |
| Donepes 5 | Anti-dementia | — |
| Prilben 10 | Neuropsychiatric | — |
| Multiple sclerosis — Eurit® | Oral cladribine, presented by the company as the first generic of Mavenclad®; high-cost line, also commercialised in Colombia | 2021 (company presentation) |
Target customers: retail pharmacy via medical prescription. Categories per S&P Capital IQ: analgesics, antipsychotics, antidepressants, anti-dementia drugs, antiepileptics and hypnotics.
Cardiometabolic (14 products)
| Brand | Description | Year |
|---|---|---|
| Hiperval Plus® | Sacubitril + valsartan, presented as the first generic of Entresto® | 2021 (company presentation) |
| Hiperval | Cardiometabolic | — |
| Antiplaq | Platelet anti-aggregant category | — |
| Bilip 10 / Bilip 20 | Lipid-lowering category | — |
| Tacardia | Cardiovascular | — |
| Vastina | Cardiovascular | — |
| Amze 5 / Amze 10 | Cardiovascular | — |
| Timezol 20 | Listed under cardiovascular by S&P Capital IQ | — |
Target customers: retail pharmacy. Categories: antihypertensives, cholesterol-lowering drugs, platelet anti-aggregants and hypoglycaemics. Market share was 1.6% (rank 15 of 44) per 2022 data.
Ophthalmology (1 product)
| Brand | Description | Year |
|---|---|---|
| Zutrab® | Biosimilar monoclonal antibody. Listed in the company presentation among 2021 high-cost leading cases; the local press (Pilar a Diario) reports an injectable monoclonal-antibody solution for age-related macular degeneration. | 2021 (company presentation) |
Other specialty and hospital lines (13 products)
| Brand / line | Description | Year |
|---|---|---|
| Amidiaz | Hospital product | — |
| Fentax | Hospital product | — |
| Dalam (hospital) | Hospital presentation | — |
| Rheumatoid arthritis line | Products not disclosed | — |
| Ever Pharma (Austria) in-licensed products | Part of three in-licensed innovative products (with Pharmacosmos); product names not disclosed | — |
Vaccines and Biotechnology (VIDA platform)
| Product / platform | Licensor / origin | Status (as of Oct-2026) |
|---|---|---|
| IPV (inactivated polio vaccine) | Licensor not disclosed per product | First private-sector sales late Mar-2026 |
| Tdap (adolescent/adult acellular triple bacterial) | Licensor not disclosed per product | First private-sector sales late Mar-2026 |
| Public-sector supply (vaccine type not disclosed) | — | Purchase order of USD 5.6 million for 1.6 million doses over 12 months (H1-2026 report) |
| Convidecia® (adenovirus-vector COVID-19 vaccine) | CanSino Biologics (China) | ANMAT certification for local production; commercial relevance now low |
| Two CanSino vaccine licences | CanSino Biologics | Licensed (FIX SCR) |
| Two Sinovac vaccine licences | Sinovac (China) | Licensed (FIX SCR) |
| One BioNet vaccine licence | BioNet (Thailand) | Licensed (FIX SCR) |
| One Biological E vaccine licence | Biological E (India) | Recently signed (FIX SCR, Jul-2026) |
| Sputnik V (historic) | RDIF / Gamaleya (Russia) | Produced 2021–2022; about 9 million doses distributed; Figueiras said the effort cost Richmond about USD 1 million (Forbes Argentina) |
| mRNA-platform capability | Plant design capability | Press reports capacity to produce mRNA vaccines; no product disclosed |
| Monoclonal antibodies / biosimilars | Internal pipeline | Plant designed for these; specific products not disclosed |
VIDA plant specifications (FIX SCR, 2026):
-
More than 11,000 m², designed for multiplatform vaccines, monoclonal antibodies and other biotech products.
-
Capacity of up to 80 million vials and 28 million syringes per year, plus a pilot plant for development and scale-up.
-
Operational areas as of 2026: zones 1 and 2, covering the pilot plant, quality control, central weighing, warehouse, packaging and fill-and-finish lines.
Financial Narrative
Basis. Table 6a uses as-originally-reported nominal ARS from S&P Capital IQ via MarketScreener. Because of IAS 29 and inflation of more than 200% in 2023, nominal growth rates massively overstate real growth. Table 6b gives FIX SCR's constant-currency (March-2026 pesos) series for FY2022–FY2025, the better basis for trend analysis. FY2021 is not available in constant currency in the sources reviewed.
6a. Income statement — as originally reported
Revenue CAGR FY2021–FY2025, nominal: about 66.3% (derived). FY2025 net income includes ARS 0.684 billion from discontinued operations (Colombia).
Dividend flags.
-
The FY2020 dividend was ARS 0.5547 per share (MarketScreener).
-
Cash dividends of ARS 59.87 million (2021) and ARS 509 million (2022) were paid per the cash-flow statement, but per-share amounts are inconsistent across providers (DivvyDiary shows ARS 1.62 paid in 2022), so FY2021/FY2022 DPS is left blank.
-
In 2026, MarketScreener records two ex-dividend dates: 14-May-2026 (ARS 16.09877) and 12-Jun-2026 (ARS 16.51447), totalling ARS 32.61 per share.
-
Ámbito's topic page headlines that Richmond made money in 2025 but would not pay dividends.
-
These sources conflict. The 2026 payments may have been charged to reserves (the company created a ARS 16,837 million optional reserve from 2024 earnings) rather than to FY2025 profit.
6b. Income statement and cash flow — constant currency
LTM to March 2026: sales ARS 131,608 million; EBITDA ARS 38,655 million (29.4% margin); FCF ARS -13,801 million. Real revenue CAGR FY2022–FY2025: about -8.4% (derived). FY2022 is inflated by pandemic vaccine deliveries to the Ministry of Health.
6c. Balance sheet — as originally reported
The company reports FY2025 working capital of ARS 742 million and a current ratio of 1.01. Intangible assets in the company's own balance sheet were ARS 41,953 million at Dec-2025, which includes capitalised development costs.
Constant-currency balance sheet (FIX SCR, March-2026 pesos):
At 31-Mar-2026: total debt ARS 215,883 million (about USD 156 million per FIX), of which 68% (USD 106 million) is owed to the VIDA trust; cash ARS 3,238 million; equity ARS 122,241 million.
6d. Cash flow — as originally reported
No share buyback programme has been disclosed: ### 6e. Ratios (S&P Capital IQ via MarketScreener; as-reported basis)
FIX SCR credit ratios (constant currency):
FIX's liquidity table in the same report shows total debt/EBITDA of 7.4x (2022), 9.8x (2023), 7.8x (2024) and 3.8x (2025), which conflicts with its Annex I. Both are reported here; Annex I appears to be the standardised series. Excluding the VIDA trust liability, FIX puts debt/EBITDA at 1.8x (LTM Mar-2026).
6f. Interim results 2026
Sources: Ámbito via Mundo Empresarial (10-May-2026); iProfesional (6-Aug-2026); company H1-2026 results report. FIX computes the Q1-2026 EBITDA margin at 11.6% against the company's 14%. The Q1-2026 RECPAM was ARS 5,176 million and the FX gain on liabilities ARS 2,801 million. Inflation was 9% in Q1 and 16.85% in H1, while the peso appreciated 5% in Q1 and depreciated about 2% over H1.
6g. Commentary on trends, inflections and drivers
Revenue. In real terms revenue contracted sharply after the pandemic: -42.9% in 2022 and -32.1% in 2023 in constant pesos, as government vaccine deliveries (Sputnik V) ended in 2022. It then recovered modestly (+8.0% in 2024, +4.9% in 2025). The FY2025 increase came with higher market share in the private channel. Sales fell in 2026 year to date (-16.7% in H1), which the company attributes to public-sector purchase timing. FIX notes that public deliveries clustered in Q4-2025, flattering FY2025 and penalising H1-2026. In USD, FY2025 sales were about USD 87 million at the year-end exchange rate (derived), versus a USD 8.5 billion Argentine pharmaceutical industry (INDEC, 2025).
Margins. This is the strongest part of the story. Gross margin rose from 54.5% to 61.7% in FY2025, as cost of goods sold fell 11.7% in real terms through productivity programmes and a richer mix of complex products. FIX notes COGS fell to 38.3% of sales from a 48.5% average in 2022–2024. EBITDA margin (FIX basis) moved from 20% in 2022–2023 to 31.8% in 2025. The 2026 inflection is negative but explicable: VIDA's unabsorbed fixed costs (about USD 2 million per quarter per FIX) compress the H1-2026 adjusted margin to the mid-teens. Excluding VIDA, management cites 20–25%. FIX expects 2026 margins slightly below 20%, recovering towards about 25% as utilisation rises.
Net income. Net income is dominated by financial results. FY2023's loss (ARS -10.85 billion nominal) reflected the December-2023 devaluation applied to USD liabilities. FY2024's profit (ARS 23.85 billion nominal) came from positive monetary-position and holding gains as the peso appreciated in real terms. FY2025's profit collapsed to ARS 3.09 billion: although operating profit grew 49%, the peso depreciated 40.8% against 31.5% inflation, producing ARS 20.5 billion of FX losses on VIDA-linked USD debt. In H1-2026 the pattern reversed again, with real peso appreciation producing a ARS 15.1 billion financial gain. Reported earnings are therefore close to a currency trade on a USD 156 million short-dollar position and say little about operating quality.
Cash flow. Cash flow is structurally weak:
-
Inventory days of 230–310 (FIX cites a 232-day five-year average) and lengthening receivables (DSO up to 138 days in 2025; receivables +58% real) absorb cash.
-
Operating cash flow averaged about USD 3 million a year over three years (FIX).
-
FCF after capex and dividends was negative in three of the last four years. FY2025 FCF was ARS -42.2 billion in March-2026 pesos, driven by ARS 41.4 billion of capex, mostly VIDA completion.
-
The company nonetheless paid ARS 2.9 billion of dividends in 2025, funded by debt.
Balance sheet. Total debt in constant pesos rose from ARS 206 billion (2024) to ARS 247 billion (2025), then fell to ARS 216 billion in March 2026 thanks to real peso appreciation. The more important change is composition: short-term debt rose to 27% of the total (from a historical average of about 10%), with USD 42.2 million due within 12 months against USD 2.3 million of liquidity. This is why FIX holds a Negative Outlook.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Richmond ownership | Function |
|---|---|---|---|
Laboratorios Richmond S.A.C.I.F. | Argentina | Parent | R&D, manufacturing (Pilar), marketing |
Compañía Inversora Latinoamericana S.A. (CILSA) | Uruguay | 100% | Holding company for foreign subsidiaries and associates |
Laboratorios Richmond México S.A. | Mexico | 99.0% indirect | Commercial / registrations |
Laboratorios Richmond Perú S.A.C. | Peru | 96.9% indirect, 3.1% direct | Commercial / business development |
Laboratorios Richmond Colombia S.A.S. | Colombia | 75.2% indirect, 24.8% direct | Commercial and distribution (local manufacturing divested in 2025) |
Laboratorios Richmond Chile Ltda. | Chile | 90% indirect | Commercial; Chilean Ministry of Health tender awards |
Medicine S.A. | Paraguay | 87.5% indirect | Distribution |
Laboratorios Richmond División Liofilizados S.A. | Argentina | 72.8% direct | Lyophilised-products plant, Pilar |
Italian subsidiary | Italy | — | — |
Fideicomiso Financiero Proyecto VIDA | Argentina | Richmond is usufructuary and holds a purchase option; consolidated economically | Owns and financed the VIDA biotech plant |
“—” = not publicly disclosed.
Revenue by Segment and Revenue by Segment (%)
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Private Market revenue (ARS Bn, nominal) | 32.64 | 78.28 | 101 |
Public Market + Foreign Trade revenue, derived as total minus private (ARS Bn, nominal) | 6.39 | 13.51 | 26 |
Total revenue (ARS Bn, nominal) | 39.03 | 91.79 | 127 |
Private Market share of total (%) | 83.6 | 85.3 | 79.5 |
Private Market YoY growth, nominal (%) | 172.2 | 139.8 | 29.0 |
Public + Foreign YoY growth, nominal (%) | -1.4 | 111.4 | 92.4 |
Channel Details
| Channel | Share of sales (%) | Derived revenue (ARS Mn, Dec-2025 pesos) | Share of EBITDA |
|---|---|---|---|
Private HIV and Oncology | 62 | 78,570 | About 75% of EBITDA (high-cost channels) |
Public tenders | 15 | 19,009 | — |
Pharmacy / prescription | 13 | 16,474 | — |
Exports and foreign subsidiaries | 10 | 12,673 | — |
Vaccines | 0 | 0 | Negative (pre-operating fixed costs) |
“—” = not publicly disclosed.
Therapeutic Line Details
| Therapeutic line | Share of sales (%) | Number of products (FIX SCR, 2026) |
|---|---|---|
HIV / Infectology | 46 | 20 |
Oncology / Onco-hematology | 23 | 24 |
Cardiometabolic | 14 | 14 |
Central Nervous System | 13 | 15 |
Ophthalmology | — | 1 |
Other (multiple sclerosis, rheumatoid arthritis, hospital) | Not disclosed (remainder about 4%) | 13 |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (ARS Bn, nominal) | 16.62 | 18.47 | 39.03 | 91.79 | 127.00 |
Gross profit (ARS Bn, nominal) | 5.04 | 8.86 | 20.31 | 50.24 | 78.45 |
Operating income / EBIT (ARS Bn, nominal) | 2.32 | 2.98 | 5.30 | 15.57 | 29.91 |
EBITDA (ARS Bn, nominal) | 2.49 | 3.33 | 6.44 | 18.25 | 33.00 |
Pre-tax income incl. unusual items (ARS Bn, nominal) | 1.42 | 0.80 | -13.92 | 28.58 | 8.10 |
Net income attributable to parent (ARS Bn, nominal) | 0.591 | 0.163 | -10.85 | 23.85 | 3.09 |
EPS basic (ARS) | 7.32 | 2.02 | -134.37 | 295.29 | 38.24 |
EPS diluted (ARS) | 7.32 | 2.02 | -134.37 | 295.29 | 38.24 |
Dividend per share declared on FY results (ARS) | — | — | — | 26.89 | — |
Gross margin (%) | 30.33 | 47.97 | 52.04 | 54.73 | 61.91 |
Operating margin (%) | 13.98 | 16.15 | 13.58 | 16.96 | 23.60 |
EBITDA margin (%) | 14.96 | 18.01 | 16.50 | 19.88 | 26.04 |
Net margin (%) | 3.56 | 0.88 | -27.80 | 25.98 | 2.44 |
Effective tax rate (%) | 57.57 | 80.06 | 21.53 | 16.68 | 73.60 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net sales (ARS Mn, Mar-2026 pesos) | 180,326 | 122,359 | 132,156 | 138,692 |
Sales growth, real (%) | -42.9 | -32.1 | 8.0 | 4.9 |
Operating EBITDA (ARS Mn, Mar-2026 pesos) | 36,957 | 24,497 | 32,055 | 44,044 |
EBITDA margin (%) | 20.5 | 20.0 | 24.3 | 31.8 |
Operating EBIT (ARS Mn, Mar-2026 pesos) | 29,811 | 17,181 | 21,582 | 32,478 |
Gross interest expense (ARS Mn, Mar-2026 pesos) | 8,932 | 8,724 | 5,718 | 16,380 |
Net result (ARS Mn, Mar-2026 pesos) | 1,556 | -34,256 | 34,330 | 3,379 |
Funds from operations (ARS Mn, Mar-2026 pesos) | -16,425 | -76,053 | 32,916 | 21,451 |
Working-capital change (ARS Mn, Mar-2026 pesos) | -25,416 | 68,197 | -24,821 | -19,409 |
Operating cash flow (ARS Mn, Mar-2026 pesos) | -41,840 | -7,856 | 8,095 | 2,042 |
Capex (ARS Mn, Mar-2026 pesos) | -65,299 | -29,482 | -6,802 | -41,355 |
Dividends paid (ARS Mn, Mar-2026 pesos) | -4,967 | 0 | 0 | -2,879 |
Free cash flow after dividends (ARS Mn, Mar-2026 pesos) | -112,106 | -37,338 | 1,293 | -42,192 |
FCF margin (%) | -62.2 | -30.5 | 1.0 | -30.4 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Net sales (ARS Mn, Dec-2025 pesos) | 120,754 | 126,726 |
Cost of goods sold (ARS Mn, Dec-2025 pesos) | -54,952 | -48,534 |
Gross profit (ARS Mn, Dec-2025 pesos) | 65,802 | 78,192 |
Gross margin (%) | 54.5 | 61.7 |
Selling expenses (ARS Mn, Dec-2025 pesos) | -33,217 | -36,295 |
Administrative expenses (ARS Mn, Dec-2025 pesos) | -12,686 | -12,221 |
Ordinary operating result (ARS Mn, Dec-2025 pesos) | 19,899 | 29,676 |
Net financial result (ARS Mn, Dec-2025 pesos) | 17,041 | -24,711 |
Interest and commissions on loans (ARS Mn, Dec-2025 pesos) | -9,012 | -14,967 |
FX difference on liabilities (ARS Mn, Dec-2025 pesos) | -17,470 | -20,463 |
Monetary position result, RECPAM (ARS Mn, Dec-2025 pesos) | 25,959 | 9,998 |
Pre-tax result (ARS Mn, Dec-2025 pesos) | 37,596 | 8,105 |
Income tax (ARS Mn, Dec-2025 pesos) | -6,272 | -5,965 |
Net result, continuing operations (ARS Mn, Dec-2025 pesos) | 31,324 | 2,140 |
Discontinued operations (ARS Mn, Dec-2025 pesos) | 0 | 684 |
Net result attributable to parent (ARS Mn, Dec-2025 pesos) | 31,368 | 3,088 |
Company-adjusted EBITDA margin (%) | 27 | 34 |
Net debt / adjusted EBITDA (x) | 5.38 | 4.86 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (ARS Bn, nominal) | 25.69 | 40.72 | 155.00 | 260.00 | 420.00 |
Cash and equivalents (ARS Bn, nominal) | 4.67 | 1.26 | 0.637 | 7.02 | 10.85 |
Cash + short-term investments (ARS Bn, nominal) | 7.17 | 2.55 | 0.823 | 9.97 | 15.35 |
Short-term debt incl. current LTD (ARS Bn, nominal) | 1.79 | 2.86 | 9.54 | 18.28 | 59.33 |
Long-term debt (ARS Bn, nominal) | 9.55 | 18.40 | 84.16 | 125.00 | 166.00 |
Total debt incl. leases (ARS Bn, nominal) | 11.48 | 21.45 | 94.15 | 144.00 | 246.00 |
Net debt (ARS Bn, nominal) | 4.32 | 18.90 | 93.33 | 134.00 | 231.00 |
Total equity (ARS Bn, nominal) | 5.38 | 10.22 | 22.95 | 65.35 | 93.04 |
Goodwill (ARS Bn, nominal) | 0.531 | 1.02 | 2.75 | 4.16 | 5.69 |
Other intangibles (ARS Bn, nominal) | 0.008 | 0.075 | 0.557 | 0.340 | 0.554 |
Capitalised development costs, deferred charges (ARS Bn, nominal) | 1.45 | 3.26 | 12.19 | 25.74 | 41.40 |
Net PP&E (ARS Bn, nominal) | 7.98 | 21.79 | 101.00 | 159.00 | 246.00 |
Inventory (ARS Bn, nominal) | 3.82 | 5.18 | 15.80 | 25.39 | 41.67 |
Trade receivables (ARS Bn, nominal) | 3.53 | 4.76 | 11.28 | 28.17 | 58.56 |
Working capital, current assets minus current liabilities (ARS Bn, nominal) | 6.10 | 5.01 | -4.91 | 11.78 | 1.00 |
Balance Sheet and Margin Analysis (%) (FY2022–FY2025)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (ARS Mn, Mar-2026 pesos) | 397,553 | 485,646 | 374,542 | 459,989 |
Cash and current investments (ARS Mn, Mar-2026 pesos) | 26,261 | 2,580 | 14,347 | 16,798 |
Short-term debt (ARS Mn, Mar-2026 pesos) | 27,905 | 29,910 | 26,315 | 64,933 |
Long-term debt (ARS Mn, Mar-2026 pesos) | 179,755 | 263,865 | 180,016 | 182,074 |
Total debt (ARS Mn, Mar-2026 pesos) | 207,660 | 293,775 | 206,331 | 247,007 |
Total equity (ARS Mn, Mar-2026 pesos) | 99,753 | 71,960 | 94,083 | 101,824 |
Short-term debt share of total (%) | 13.4 | 10.2 | 12.8 | 26.3 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (ARS Bn, nominal) | 3.73 | -4.29 | -2.51 | 5.62 | 1.87 |
Capex, PP&E (ARS Bn, nominal) | -5.30 | -6.69 | -9.40 | -4.72 | -37.79 |
Capitalised intangibles / development (ARS Bn, nominal) | -0.631 | -0.831 | -3.11 | -4.08 | -16.54 |
Free cash flow, OCF minus PP&E capex (ARS Bn, nominal) | -1.57 | -10.98 | -11.91 | 0.90 | -35.92 |
Dividends paid (ARS Bn, nominal) | -0.060 | -0.509 | 0 | 0 | -2.63 |
Share buybacks (ARS Bn, nominal) | 0 | 0 | 0 | 0 | 0 |
Net debt issued (ARS Bn, nominal) | 9.19 | 1.82 | 9.25 | 12.46 | 57.18 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity (%) | 11.37 | 1.54 | -39.90 | 41.29 | 2.39 |
Return on assets (%) | 7.51 | 4.11 | 2.35 | 3.26 | 4.90 |
Return on total capital, ROIC proxy (%) | 11.77 | 5.78 | 3.07 | 4.19 | 6.09 |
Current ratio (x) | 1.66 | 1.55 | 0.86 | 1.21 | 1.01 |
Quick ratio (x) | 1.20 | 0.92 | 0.40 | 0.74 | 0.65 |
Total debt / equity (%) | 213.63 | 209.94 | 410.21 | 219.76 | 264.82 |
Net debt / EBITDA (x) | 1.71 | 5.56 | 14.19 | 7.30 | 6.81 |
EBIT / interest expense (x) | 3.12 | 2.08 | 1.00 | 4.73 | 2.00 |
EBITDA / interest expense (x) | 3.39 | 2.37 | 1.24 | 5.57 | 2.27 |
Asset turnover (x) | 0.86 | 0.41 | 0.28 | 0.31 | 0.33 |
Days sales outstanding (days) | 86.14 | 114.98 | 121.97 | 105.11 | 137.70 |
Days inventory outstanding (days) | 98.55 | 239.77 | 311.17 | 263.26 | 283.78 |
Days payable outstanding (days) | 130.63 | 396.42 | 383.54 | 451.29 | 262.73 |
Cash conversion cycle (days) | 54.05 | -41.66 | 49.61 | -82.92 | 158.75 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total debt / EBITDA, Annex I (x) | 5.6 | 12.0 | 6.4 | 5.6 |
EBITDA / gross interest (x) | 4.1 | 2.8 | 5.6 | 2.7 |
Implicit cost of funding (%) | 4.2 | 3.5 | 2.3 | 7.2 |
Key Financials and Margin Analysis (%)
| Metric | Q1-2025 | Q1-2026 | H1-2025 | H1-2026 |
|---|---|---|---|---|
Net sales (ARS Mn, restated to period-end pesos) | 35,827 | 28,744 | 76,197 | 63,487 |
Sales growth (%) | — | -19.8 | — | -16.7 |
Gross margin (%) | 53.7 | 55.3 | 59.7 | 59.6 |
Ordinary operating result (ARS Mn) | — | 151 | — | 1,113 |
Unabsorbed VIDA fixed costs in Other Expenses (ARS Mn) | — | 2,708 | — | 8,023 |
Company-adjusted EBITDA margin (%) | 28 | 14 | — | — |
Adjusted EBITDA margin excluding VIDA start-up (%) | — | 20 | — | 25 |
Net financial result (ARS Mn) | 2,755 | 23,252 | -7,724 | 15,063 |
Pre-tax result (ARS Mn) | — | — | — | 16,788 |
Net result (ARS Mn) | 7,465 | 21,219 | — | — |
Total comprehensive result (ARS Mn) | — | 20,493 | — | 13,697 |
Net debt / adjusted EBITDA (x) | 19.24 | 53.21 | — | 20.03 |
Revenue by Region (%) and Revenue by Region
| Region / metric | FY2024 | FY2025 |
|---|---|---|
Exports, share of consolidated sales (%) | 3.7 | 5.0 |
Exports, derived value (ARS Mn, Dec-2025 pesos) | 4,468 | 6,336 |
Domestic and foreign-subsidiary sales, derived value (ARS Mn, Dec-2025 pesos) | 116,286 | 120,390 |
Exports + foreign subsidiaries, share of sales (%) | — | 10 |
Country / Region Details
| Country / region | Presence | Recent trajectory |
|---|---|---|
Argentina | Core market, about 90% of sales; ranked 21st of about 330 laboratories by sales (Dec-2025) | Private channel growing in volume and mix; public channel volatile and seasonal |
Colombia | Subsidiary (100% economic interest); high-cost products (multiple sclerosis, HIV), primary care, cardiometabolic, CNS | Manufacturing exited in 2025 (sale to Laboratorios Raven; Bogotá plant sold in Q4-2025). Now a commercial and distribution hub for Argentine-made products — the main declining line in reported revenue, by design |
Chile | Subsidiary (90%) | Chilean Ministry of Health tender awards |
Paraguay | Medicine S.A. (87.5%) | New product registrations in progress |
Mexico | Subsidiary (99%) | Registrations in progress; long pre-operational |
Peru | Subsidiary (100% economic) | Business development |
Ecuador | No subsidiary identified | Business development |
Uruguay | CILSA holding company | Registrations in progress |
Italy | Subsidiary (details not disclosed) | — |
Rest of Latin America | Partners in Bolivia, Brazil, Costa Rica, Dominican Republic and others (28 strategic partners) | Distributor model |
Middle East / Africa / Asia | Syria (public tenders); registrations in the Philippines, South Africa and Tunisia | Early-stage diversification |
“—” = not publicly disclosed.
Share Price and Share Count (millions)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Year-end reference price (ARS) | 115.50 | 222.00 | 389.00 | 698.50 | 1,795.00 | 1,975.00 |
Shares outstanding (millions) | 80.75 | 80.75 | 80.75 | 80.75 | 80.75 | 80.75 |
Year-end market cap, derived (ARS Bn, nominal) | 9.33 | 17.93 | 31.41 | 56.40 | 144.95 | 159.48 |
Share Price & Returns
| Horizon | Performance |
|---|---|
Year to date (from ARS 1,975) | -24.8% (MarketScreener: -24.81%) |
1-year | Not publicly disclosed (exact Oct-2025 price unavailable) |
About 3-year (from Dec-2023, ARS 698.50) | +112.6% |
About 5-year (from Dec-2020, ARS 115.50) | +1,185.7% |
Valuation Multiples
| Multiple | Richmond | Basis |
|---|---|---|
Market cap | ARS 119.9 billion (about USD 78 million) | ARS 1,485 × 80.75 million shares; FX ARS 1,540 |
Enterprise value | About ARS 332.6 billion | Market cap + total debt ARS 215.9 billion − cash ARS 3.2 billion (Mar-2026) |
EV / Sales (LTM Mar-2026) | About 2.5x | EV / ARS 131.6 billion |
EV / EBITDA (LTM Mar-2026) | About 8.6x | EV / ARS 38.7 billion (FIX) |
EV / Sales FY2025 | 3.08x | MarketScreener (at its price date) |
P/E FY2025 | 51.6x (MarketScreener) / about 38.8x (derived: ARS 119.9 billion / ARS 3.09 billion) | Different price dates and currency bases |
P/B | About 0.98x | Market cap / total equity ARS 122.2 billion (Mar-2026) |
Dividend yield (2026 distributions, ARS 32.61 per share) | About 2.2% | ARS 32.61 / ARS 1,485 |
Year Paid Details
| Year paid | Amount per share (ARS) | Notes |
|---|---|---|
| 2021 | 0.5547 | On FY2020 results |
| 2022 | Cash paid ARS 509 million in aggregate (per-share amount inconsistent across sources) | On FY2021 results (board proposed more than ARS 112 million) |
| 2025 | 26.8897 | Paid 15-May-2025 |
| 2026 | 16.09877 + 16.51447 = 32.61 | Ex-dates 14-May and 12-Jun-2026; conflicts with Ámbito headline |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
FIX SCR (Fitch affiliate; national scale) — long-term issuer and ONs Series III, VI-B, VI-C, VIII | A-(arg) | Negative | 22-Jul-2026 |
FIX SCR — short-term issuer and ON Series VII | A2(arg) | — | 22-Jul-2026 |
FIX SCR — shares | Category 1 | — | 22-Jul-2026 |
FIX SCR — historic long-term | A(arg) | Stable | May-2022 |
FIX SCR — VIDA sustainable bond review | BSS1(arg) | — | 2021 |
Moody's / S&P / Fitch international | Not rated | — | — |
Bucket Details
| Bucket | Amount (USD Mn) | Composition |
|---|---|---|
Total debt | 156 | 68% VIDA trust, 11% ONs, remainder bank debt |
Current (≤12 months) | 42.2 | Bank loans, cheques and promissory notes 25.1; ONs 17.1 (4.5 due Aug–Sep 2026; 11.0 due Dec-2026) |
VIDA trust liability | 106 | Long-term; participation certificates mature 2045; serviced from VIDA results |
ON Serie III Clase Dólar | Residual of USD 7.57 million original | Matures 13-Nov-2030; 5% fixed plus revenue participation |
ON Serie VI B / C | USD 3.96 million / UVA 2.76 million original | Final maturity 13-Aug-2026 |
ON Serie VII A / B | ARS 11,120 million / USD 2.50 million | Bullet on 10-Dec-2026 |
ON Serie VIII A / B / C | Up to USD 13 million (expandable to 20 million) | 24 months; amortising at 18/21/24 months |
Available facilities | 5.7 working capital + 3.2 investment + 7.3 Ministry invoice discounting | Undrawn lines (Jul-2026) |
Analyst Conclusions
Management guidance. No quantitative guidance is published. Management's stated expectations:
-
Margins and leverage ratios normalise as VIDA's projected sales materialise and as Argentine inflation and FX converge.
-
Further regulatory approvals for VIDA products are expected in the coming months.
-
Vaccines could become up to 35% of revenue over the coming years (via FIX SCR).
External expectations (FIX SCR base case, not consensus):
-
2026 EBITDA margin slightly below 20%, rising towards 25%.
-
Debt/EBITDA about 8x in 2026 (about 2x ex-VIDA trust), then deleveraging.
-
VIDA profitable in 2027.
-
FCF trending to neutral or positive as capex declines.
There is no sell-side consensus.
Bull case:
-
The core business is high quality and improving. FY2025 gross margin of 61.7% and EBITDA margin of 31.8–34%, with a 56.9% HIV share, point to a durable cash-generating franchise. Excluding VIDA start-up costs, the H1-2026 adjusted EBITDA margin was still 25%.
-
VIDA's operating leverage is large relative to market cap. About USD 8 million a year of unabsorbed fixed cost is already in the P&L. Any utilisation gain, such as the USD 5.6 million public order, flows heavily to EBITDA. Vaccines at even half of management's 35% revenue ambition would transform scale for a company valued at about USD 78 million.
-
Valuation is undemanding on assets. The shares trade at about 1x book, about 2.5x LTM EV/Sales and about 8.6x EV/EBITDA, where EV includes a USD 106 million project liability serviced from VIDA's own cash flows. The stock is down 24.8% year to date despite first VIDA revenues.
Bear case:
-
Liquidity is the binding constraint. USD 2.3 million of liquidity faces USD 42.2 million of 12-month maturities. Operating cash flow averages only about USD 3 million, and FIX explicitly links any downgrade to failure to refinance 2026 maturities.
-
Cash conversion is structurally poor. Inventory days above 230, DSO of 138 and public/payer arrears consume most EBITDA. FCF after dividends was ARS -42 billion in 2025, yet dividends were still paid.
-
Earnings are a currency bet, and VIDA economics accrue first to trust holders. With 82–83% of liabilities in or linked to USD, reported profits swing with the peso. VIDA profits are earmarked to repay the trust through 2045, so equity holders capture only the residual, after a demonstrated record of delays and overruns.
Concluding analyst verdict.
Laboratorios Richmond is two companies sharing one balance sheet. The first is a highly profitable niche specialty-generics business. It dominates Argentine HIV therapy, has credible first-generic know-how in complex molecules, and delivered a step-change in efficiency in 2025, lifting gross margin above 61% and EBITDA margin above 30%. Stripped of everything else, that business would merit a quality premium in the Argentine market.
The second is a venture-stage vaccine and biotech manufacturer. VIDA is a modern, licensed, scalable asset that only began selling product in March 2026. It currently burns roughly USD 8 million a year of unabsorbed fixed cost, and it carries a USD 106 million trust liability that is senior in economic priority to shareholders.
The problem is that the first business's cash flow has not been enough to fund the second's delays. Working-capital intensity (inventory above 230 days, DSO near 140) and payer arrears have converted strong EBITDA into negligible operating cash. The gap has been filled with short-term peso and dollar notes, pushing the short-term share of debt to 27% and earning a Negative Outlook from FIX SCR.
Reported earnings are an unreliable guide: they swing by tens of billions of pesos with the real exchange rate. Investors should focus on operating EBITDA, cash conversion and VIDA utilisation instead.
Our assessment is that the equity is a high-risk, execution-dependent option on VIDA, underpinned by a valuable core franchise and an asset-backed valuation near book value. The next six months are decisive. If Richmond refinances its December-2026 maturities on longer terms, delivers the public vaccine order and shows sequential improvement in VIDA absorption, the Negative Outlook could stabilise and the discount narrow. Failure on refinancing would turn a liquidity squeeze into a solvency debate. Position sizing should reflect that binary.
SOURCES (paraphrased; no verbatim reproduction)
1: FIX SCR, "Laboratorios Richmond S.A.C.I.F. — Informe de Calificación (ON Serie VIII)", bst.com.ar — 22-Jul-2026 — Ratings, debt, liquidity, channel mix, subsidiaries, shareholders, VIDA specifications, constant-currency financials
2: Laboratorios Richmond, "Informe de Resultados Año 2025", via pharmabiz.net — 6-Mar-2026 — FY2024–FY2025 P&L and balance sheet, adjusted EBITDA, Colombia discontinued operations
3: Laboratorios Richmond, "Informe de Resultados 2T 2026", via pharmabiz.net — Aug-2026 — H1-2026 results
4: Laboratorios Richmond, Hecho Relevante — OraQuick authorisation, via pharmabiz.net — 13-Jul-2026 — OraSure distribution
5: MarketScreener (S&P Capital IQ data): income statement, balance sheet, cash flow, ratios, segments, dividends, quotes — Accessed 6/7-Oct-2026 — FY2021–FY2025 nominal financials, prices, dividends
6: Mundo Empresarial, summarising Ámbito: "Laboratorios Richmond triplicó sus ganancias…" — 10-May-2026 — Q1-2026 results
7: iProfesional, "La fábrica de vacunas de Richmond ya funciona…" — 6-Aug-2026 — H1-2026 results, VIDA, public order
8: Ámbito topic page, Laboratorios Richmond — Accessed Oct-2026 — Headlines (dividends, Colombia, Bamberg, OraQuick)
9: El Heraldo (Colombia), sale of assets to Raven Colombia — 26-Aug-2025 — Colombia divestiture
10: iProfesional, Colombia sale article — 2025 — Colombia divestiture, División Liofilizados
11: El Cronista, OraSure agreement article — 2026 — OraQuick
12: FIX SCR, ON Serie VI rating report — 6-Aug-2024 — VIDA usufruct, historic context
13: FIX SCR, ON Serie VII rating report and supplements (BST) — Dec-2025 — Series VII terms
14: FIX SCR, FF Proyecto VIDA report — 16-May-2022 — Historic rating A(arg) Stable
15: Company institutional presentation, ON Serie VI (Allaria) — 2024 — Therapeutic mix, flagship launches, 26 countries
16: iProfesional, "Richmond obtiene fondos de inversores locales…" — 20-Dec-2022 — History, market shares, 2021 sales
17: iProfesional, "Laboratorios Richmond presenta a su nuevo CEO" — Dec-2022 — Leadership change
18: iProfesional, "Richmond cambia vacuna rusa por china" — 2022 — CanSino deal, VIDA financing
19: Mercado, "Laboratorios Richmond comienza a cotizar en bolsa" — 2017 — IPO
20: Pharmabiz, Uruguay company / Expofarma articles — c. 2017 — Regional expansion
21: Diario de Cuyo / Infobae; Consultorsalud; El Litoral; Hoy Día; Forbes Argentina; BA Times — 2021–2022 — Sputnik V, VIDA trust, Figueiras profile
22: El Heraldo (AR), CanSino Convidecia certification — 2022/23 — Vaccine licensing
23: Economía Sustentable, biosimilars article — c. 2020 — 2019 data
24: Boletín Oficial, board composition — 2019 — Directors
25: Investing.com / Simply Wall St / Yahoo Finance / TradingView profiles — Accessed Oct-2026 — Board list, IPO date, incorporation date, ISIN
26: DivvyDiary dividend page — Accessed Oct-2026 — Dividend history
27: Pilar a Diario topic page — Accessed Oct-2026 — Ophthalmology launch, VIDA milestones
28: CILFA sector reports (via Mundo Empresarial) and INDEC data (via FIX SCR) — 2025–2026 — Industry context
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / notes | Prior roles / background | Education | Age |
|---|---|---|---|---|---|
Marcelo Rubén Figueiras | President / Chairman of the Board; largest shareholder (38.5%) | President at least since the 2019 board term and the public face of the company for well over a decade | Business interests in insurance and banking; former shareholder of Banco Finansur (sold to Cristóbal López). Received the OEI Ibero-American Prize for Cooperation for Development (June, Madrid; year c. 2023/24) | Accountant, University of Buenos Aires (BA Times) | Born 16-Nov-1963 (62) |
Juan Manuel Artola | Vice-President of the Board (from Dec-2022); former CEO | CEO at the 2017 IPO; moved to Vice-Chair in Dec-2022. Some data providers (Yahoo, Simply Wall St) still list him as CEO — data lag | Long-time executive director | — | — |
Pablo García Santillán | Chief Executive Officer (appointed Dec-2022, reporting to Artola) | — | More than 30 years in pharma; 7 years as General Manager of Laboratorios IMA (Cristália group, Brazil); previously regional Marketing and Sales Director at Siegfried (based in Bogotá) | — | — |
Rubén Jorge Álvarez | Chief Financial Officer | Listed by data providers since 2022; alternate director in the 2019 board | — | — | — |
R. A. Patricio Carballés | Director; Vice-President of Legal Affairs; investor contact on the FY2025 results release | Director since c. 2022; alternate director in 2019 | — | — | — |
Elvira Beatriz Zini | Director | Director at least since 2019 | — | — | — |
Ricardo José Bertero | Independent Director | Director at least since 2019 | — | — | — |
Daniel Jorge Razetto | Independent Director | Since c. 2022 | — | — | — |
María Laura Leguizamón | Director | Since c. 2022 | — | — | — |
Roberto A. Persico | Director | Since c. 2022 | — | — | — |
Eduardo César Savastano | Alternate Director | Director in 2019; alternate since c. 2022 | — | — | — |
Eugenio Gabriel Noziglia / Eugenio Mariano Noziglia | Alternate Directors | — | — | — | — |
Alberto Daniel Serventich | Shareholder (15.2%); director in the 2019 board | — | — | — | — |
Santiago Lizzoli | Chairman of the Supervisory Committee (Comisión Fiscalizadora) | Since c. 2021 | — | — | — |
Jorge Luis Colombo | Member of the Supervisory Committee | — | — | — | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Executive | Stock |
|---|---|
All executives and directors | No equity plans disclosed |
Major Shareholders
| Holder | Stake (% of capital) | Class |
|---|---|---|
Marcelo Rubén Figueiras | 38.5 | A |
Busnel S.A. | 24.7 | A |
Alberto Daniel Serventich | 15.2 | A |
Martín Eduardo Nadler | 3.9 | A |
Free float (BYMA) | 17.54 | B |
Competitive Landscape
Key Competitors
| Competitor | Ownership | Segments where it competes with Richmond | Relative positioning |
|---|---|---|---|
Roemmers | Private, Argentine | Cardiometabolic, CNS (retail prescription) | Historically Argentina's top lab by sales; far larger retail franchise |
Laboratorios Elea Phoenix | Private, Argentine | CNS, cardiometabolic, retail | Larger retail presence |
Gador | Private, Argentine | CNS, cardiometabolic, oncology | Larger and broader portfolio |
Laboratorios Bagó | Private, Argentine | Retail prescription; regional exports | Much larger regional footprint |
Laboratorios Casasco | Private, Argentine | Retail, cardiometabolic | Larger retail scale |
Raffo / Monte Verde (Insud group) | Private, Argentine | HIV and oncology generics | Direct competitor in high-cost generics |
mAbxience (Insud group) | Private, Argentine/Spanish | Biosimilar monoclonal antibodies | More advanced global biosimilar player; competitor for VIDA's biosimilar ambitions |
Sinergium Biotech (Insud group) | Private, Argentine | Vaccines (flu, HPV, pneumococcal via tech transfer) | Incumbent local vaccine producer; most direct VIDA competitor |
Biogénesis Bagó | Private, Argentine | Biologics manufacturing capacity (primarily animal health) | Biotech manufacturing peer |
Laboratorio Varifarma / Eriochem / Filaxis / LKM | Private, Argentine | Oncology generics, onco-hematology injectables | Specialist oncology competitors |
Gilead, ViiV/GSK, MSD, Janssen | Multinationals | HIV originators; vaccines (GSK, MSD, Sanofi, Pfizer) | Originator pricing; Richmond competes on price and FDC innovation |
Sanofi, GSK, MSD, Pfizer (vaccines) | Multinationals | Calendar vaccines incl. IPV, Tdap | Dominant global suppliers; PAHO Revolving Fund pricing sets benchmark |
Laboratorios Raven | Private, Colombia | Colombian generics | Buyer of Richmond's Colombian manufacturing; now a partner/competitor locally |
Competitors by Segment
| Line | Rank | Share (%) | Date |
|---|---|---|---|
HIV / Infectology | 1 | 56.9 | Dec-2025 (FIX SCR) |
HIV / Infectology | 1 of 16 | 52.9 | c. 2022 (iProfesional) |
Oncology and Onco-hematology | 19 of 59 | 1.1 | c. 2022 |
Cardiometabolic | 15 of 44 | 1.6 | c. 2022 |
Total Argentine market | 21 of about 330 | — | Dec-2025 |
“—” = not publicly disclosed.
Competitor Detail
| Metric (FY2025) | Laboratorios Richmond |
|---|---|
Revenue | ARS 126.7 billion (about USD 87 million) |
Revenue growth (real) | +4.9% |
EBITDA margin | 31.8% (FIX) / 34% (company-adjusted) |
R&D intensity (expensed) | about 5.0% (plus capitalised development) |
Listed | Yes (BYMA) |



